Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study (Q45022423)

8 December 2017

title

Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study (English)

1 reference

8 December 2017

4

Stephan Rössner

1 reference

8 December 2017

Luc F Van Gaal

1

1 reference

8 December 2017

André J Scheen

2

1 reference

8 December 2017

Aila M Rissanen

3

1 reference

8 December 2017

Corinne Hanotin

5

1 reference

8 December 2017

Olivier Ziegler

6

1 reference

8 December 2017

RIO-Europe Study Group

7

1 reference

8 December 2017

publication date

15 April 2008

1 reference

8 December 2017

published in

European Heart Journal

1 reference

8 December 2017

volume

29

1 reference

8 December 2017

issue

14

1 reference

8 December 2017

page(s)

1761-1771

1 reference

Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology

8 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHN076

Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Ph

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHN076

Mechanisms linking obesity with cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHN076

Endocannabinoid control of food intake and energy balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHN076

The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHN076

Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHN076

Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHN076

The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHN076

The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHN076

Cannabinoid receptors regulate Ca(2 ) signals and insulin secretion in pancreatic beta-cell.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHN076

Activation of the peripheral endocannabinoid system in human obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHN076

Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHN076

Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHN076

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHN076

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHN076

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHN076

The metabolic syndrome--a new worldwide definition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHN076

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHN076

The MOS 36-ltem Short-Form Health Survey (SF-36)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHN076

Construct Validity of the Impact of Weight on Quality of Life Questionnaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHN076

The hospital anxiety and depression scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHN076

A sharper Bonferroni procedure for multiple tests of significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHN076

Diabetes, prediabetes, and cardiovascular risk: shifting the paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHN076

Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHN076

21 January 2018

Identifiers

DOI

10.1093/EURHEARTJ/EHN076

1 reference

8 December 2017

1 reference